• CIRM Scientific and Medical Research Funding Working Group ...


  •   
  • FileName: 101106_item_9a.pdf [preview-online]
    • Abstract: Director of Hematology-Oncology Research at the Mount Sinai School of Medicine in ... Hematology (2000), the Samuel Rosenthal Prize for Excellence in Pediatrics (2002) ...

Download the ebook

Agenda Item # 9 a
10/11/06 ICOC Meeting
CIRM Scientific and Medical Research Funding Working Group
Biographical Information of Candidates to serve as Alternate Scientific Members
Margaret Baron, MD, PhD
Dr. Margaret Baron is the Irene and Dr. Arthur M. Fishberg Professor of Medicine and
Director of Hematology-Oncology Research at the Mount Sinai School of Medicine in
New York. After receiving her MD from Harvard Medical School and her PhD from the
Massachusetts Institute of Technology, she was Assistant, then Associate Professor at
Harvard University before moving to the Mount Sinai School of Medicine in 1997.
Currently, she is also Assistant Director of the Mount Sinai MSTP Program, Co-Director
of the Mechanisms of Disease and Therapies Program, and the Interim Co-Director of
The Black Family Stem Cell Institute. Her numerous awards and honors include being
elected as a member of the American Society for Clinical Investigation in 2000, receiving
the Richard E. Rosenfield Faculty Achievement Award in 2000, and the American
Cancer Society Research Recognition Award in 2004. Dr. Baron has served on review
panels for the American Cancer Society and the National Institutes of Health (NIH), and
chaired Special Emphasis Panels for the NIH. She has also chaired the Scientific
Subcommittee on Hemoglobin and Red Cells for the American Society for Hematology
and serves on the editorial board of the journal StemCells. Her research focus is on
development of the hematopoietic and cardiovascular systems and on molecular
regulation of mammalian stem cell differentiation and proliferation.
Kevin Eggan, PhD
Dr. Kevin Eggan received his PhD in Biology from the Massachusetts Institute of
Technology in February of 2003. In September 2003, Dr. Eggan joined Harvard
University as a Junior Fellow in the Harvard Society of Fellows, where he is now an
Assistant Professor of Molecular and Cellular Biology. In July 2005, Dr. Eggan became
the founding member and Assistant Investigator of the Stowers Medical Institute (SMI) of
Cambridge, Mass. and a Principal Investigator of the Harvard Stem Cell Institute. SMI's
support of his research is similar to the support provided to researchers by the Howard
Hughes Medical Institute. In September 2006, Dr. Eggan received the prestigious
MacArthur Fellowship award. Currently a member of the CIRM Standards Working
Group, he has made significant contributions towards the development of the CIRM
Medical and Ethical Standards, now under consideration by the Office of Administrative
Law of the state of California. His research interests focus on the mechanisms by which
nuclear reprogramming occurs and the identities of the molecular machinery that
accomplishes reprogramming.
Steve Emerson, MD, PhD
Dr. Steve Emerson is the Francis C. Wood Professor in Medicine, Pathology and
Pediatrics and Chief of Hematology/Oncology and Cancer Center at the University of
Pennsylvania where he is also Associate Director for Clinical Research and Director of
the University’s Institute for Stem Cell Biology and Regenerative Medicine. After
receiving his MD and PhD from Yale University, Dr. Emerson interned at Massachusetts
General Hospital followed by clinical and research fellowships at Brigham and Women’s
Hospital, Dana-Farber Cancer Institute and Children’s Hospital Medical Center in
Boston. He has published over 151 scientific articles and received numerous awards for
1
Agenda Item # 9 a
10/11/06 ICOC Meeting
his research. Dr. Emerson served on the editorial boards of Blood, Experimental
Hematology and StemCells, as well as on numerous study sections for the National
Institutes of Health. In 2007, he will be the deputy editor of the Journal of Clinical
Investigation. The primary aim of Dr. Emerson’s research is to understand the
regulation of human hematopoietic stem cell self-renewal and differentiation and to apply
this knowledge to the development of novel cellular and molecular therapeutics utilizing
bone marrow stem cells. In addition, his laboratory studies the molecular mechanisms
underlying the development of graft-versus host disease.
Todd R, Evans, PhD
Dr. Todd Evans is Professor in the Department of Developmental and Molecular Biology
and Director of the Graduate Program in Biomedical Sciences at Albert Einstein College
of Medicine which administers the academic progress for over 350 PhD and MD/PhD
students. After receiving a PhD (1987) in molecular biology from the Department of
Genetics and Development at Columbia University, he worked as a post-doctoral fellow
with Dr. Gary Felsenfeld at the NIH, where he identified and cloned the transcription
factor GATA-1. In 1990, he joined the University of Pittsburgh, Department. of Biological
Sciences as an Assistant Professor. His work at Pittsburgh led to the discovery of the
cardiogenic factors GATA-4/5/6. He has served on numerous scientific review boards,
including study sections for the American Cancer Society, the American Heart
Association, and the National Institutes of Health (for both Hematology and Cardiology).
In 2001, Dr. Evans was elected to the Leo M. Davidoff Society for excellence in teaching
and received the Samuel Rosen Outstanding Teacher Award in 2002. Research in the
Evans laboratory is directed toward understanding early embryonic development of
blood and heart; the focus is on the function and regulation of GATA factors, a small
group of highly conserved transcriptional regulatory proteins.
Gordon Fishell, PhD
Dr. Gordon Fishell is Professor in the Department of Cell Biology at the Skirball Institute
and the Department of Cell Biology, New York University Medical Center. He has co-
ordinated the Skirball Institute's Developmental Genetics Program since the autumn of
1994 and is currently Professor and Coordinator of the Smilow Neuroscience Program.
After receiving his PhD in neurobiology from the University of Toronto in 1989, he was a
postdoctoral fellow in Dr. M.E. Hatten’s laboratory at Columbia University until 1992
when he joined the Rockefeller University as an Assistant Professor. Dr. Fishell was
named a New York Spinal Cord Research Foundation Researcher and has received
numerous awards including the Richardson Award, the McMurrich Award, the Irma T.
Hirschl Career Scientist Award and the Anthony Corso Memorial Child Brain Tumor
Foundation Award. He serves on the editorial boards of Nature Reviews
(Neuroscience), Neurosignals, The Journal of Neuroscience, Developmental
Neuroscience, and Genes and Development, and is a regular member of NIH study
sections. Dr. Fishell and his laboratory study the mechanisms that pattern the
mammalian brain with a focus on the interface between regional patterning and the
control of neuronal stem cells.
John Gearhart, PhD
John D. Gearhart is the C. Michael Armstrong Professor of Medicine and director of the
Stem Cell Program at Johns Hopkins University. He holds professorships in Physiology,
2
Agenda Item # 9 a
10/11/06 ICOC Meeting
Comparative Medicine, and Gynecology and Obstetrics in the School of Medicine, and in
Biochemistry and Molecular Biology in the Bloomberg School of Public Health. He also
serves as Director of Research for the Department of Gynecology and Obstetrics, and
the Division of Developmental Genetics, and has been a member of the Medical
Genetics Center and the Center for Reproductive Biology since 1990. Dr. Gearhart
received his PhD in genetics from Cornell University. His research has focused on the
way genes regulate the formation of tissues and embryos; for the last 20 years he has
attempted to determine the exact causes of mental retardation and other birth defects in
Down's Syndrome. Dr. Gearhart led one of the two laboratories that first published on
human pluripotent stem cells in 1998, and has consequently been involved in debates
on all aspects of the science, ethics and public policy of human stem cell research. His
current research is on the derivation of specialized, mature cells from embryonic stem
cells and their use to treat various models of degenerative disorders and injuries. The
human cells are also being investigated as vehicles for gene therapies.
Margaret Goodell, PhD
Dr. Margaret A. Goodell is Professor of Pediatrics, Molecular and Human Genetics, and
Immunology, and director of the Stem Cells and Regenerative Medicine Center at Baylor
College of Medicine. She received her PhD from Cambridge University in England
where she worked on embryonic stem cell gene targeting with Dr. Andrew Smith. She
then joined Dr. Richard Mulligan’s laboratory as a postdoctoral fellow working on
hematopoietic stem cells at the Whitehead Institute for Biomedical Research at MIT and
at Harvard University. In 1997, she joined the faculty of the Center for Cell and Gene
Therapy at Baylor where her research focuses on the basic biology of hematopoietic
stem cells and the molecular mechanisms controlling their behavior. Among the many
awards received by Dr. Goodell are the Leukemia and Lymphoma Society Scholar
Award and the W.M. Keck Foundation Award (2001), the Michael E. DeBakey MD
Excellence in Research Award (2004) and the Stohlman Scholar Award (2006). Her
professional activities include service as a board member and chair of the Audit
Committee of the International Society for Stem Cell Research, and on the editorial
boards of StemCells, PLos Biology, Blood, Experimental Hematology and Molecular
Therapy. She has also served on review panels for the NIH, the Muscular Dystrophy
Association and the Wellcome Society.
Ann Kiessling, PhD
Dr. Kiessling received a PhD in Biochemistry/Biophysics from Oregon State University in
1971 and served as an Assistant, then Associate Professor at Oregon Health Sciences
University from 1977 to 1985 and as an Associate Professor at Harvard Medical School
since 1985. She started the first In Vitro Fertilization (IVF) laboratory in Oregon and was
recruited to Harvard to head up an IVF laboratory at Brigham and Women's Hospital
where she has continued her research in both early embryo development and semen
transmission of HIV. Professor Kiessling made important discoveries about early
embryo development and is currently developing reliable systems for parthenogenetic
activation of mammalian eggs, including human, investigating the role of endogenous
reverse transcriptase in pluripotent stem cell differentiation, and developing strategies for
maturing oocytes from human embryonic stem cells. She serves as a scientific member
of CIRM’s Standards Working Group, providing critical expertise particularly with respect
to protocols related to oocyte donation for research purposes.
3
Agenda Item # 9 a
10/11/06 ICOC Meeting
Diane Krause, MD, PhD
Dr. Diane Krause is Associate Professor at the Yale University School of Medicine,
Director of the Stem Cell Processing Laboratory and Associate Director of both the Yale
Stem Cell Program and the Blood Bank at the Yale-New Haven Hospital. After receiving
her MD in Medicine and her PhD in Cell Biology at University of Pennsylvania, Krause
was a post-doctoral fellow at the Johns Hopkins Oncology Center before joining Yale in
1995. She has served extensively on NIH study sections as well as other national and
international review committees including the Wellcome Trust Review Committee and
the Agence National de la Recherche. Dr. Krause also serves on several state, national
and international committees engaged in critical scientific and policy decision-making
with regard to stem cell research. She has published extensively. Her work centers on
characterizing hematopoietic stem and progenitor cells and defining the molecular
mechanisms that regulate their self-renewal and differentiation with the goal of improving
strategies for bone marrow/stem cell transplantation and developing novel strategies for
treating leukemia and lymphoma.
Sean Morrison, PhD
Sean J. Morrison is Associate Professor at the University of Michigan, Director of the
University of Michigan Center for Stem Cell Biology, the Henry Sewall Professor in
Medicine and a Howard Hughes Medical Institute Investigator. He obtained his PhD in
Immunology at Stanford University (1996), working with Dr. Irving L. Weissman, followed
by a postdoctoral fellowship at Caltech (1999) in Dr. David J. Anderson’s laboratory.
Since 1999, Dr. Morrison has been at the University of Michigan where his laboratory
studies the mechanisms that regulate stem cell function in the nervous and
hematopoietic systems. Dr. Morrison’s many honors and awards include being a Searle
Scholar (2000-2003), being named to Technology Review Magazine’s list of 100 young
innovators (2002), recipient of the Wired Magazine Rave Award for Science (2003) and
the Presidential Early Career Award for Scientists and Engineers from the White House
(2003). In addition to stem cell research, Dr. Morrison has been active in public policy
issues surrounding stem cells as a director of the International Society for Stem Cell
Research, as a member of the American Society for Cell Biology Public Policy
Committee, and as the director of the University of Michigan Center for Stem Cell
Biology. In recognition of his public policy work at the state level, the Detroit News
recently named Dr. Morrison one of it’s Michiganians of the Year (2006).
Alan Rosmarin, MD
Alan Rosmarin is Associate Professor of Medicine and of Molecular Biology, Cell Biology
and Biochemistry at Brown University. He is also director of the Brown University
Oncology Group and recently established a successful program in Oncology at Moi
Teaching and Referral Hospital in Eldoret, Kenya. After receiving his medical degree
from UMDNJ - Rutgers Medical School he served as an intern, resident and clinical
fellow at Beth Israel Hospital/Harvard Medical School. His clinical practice is primarily
directed towards Hematology and Hematologic malignancies. Widely recognized for his
work, he has received many honors including the National Research Service Award and
the Physician Scientist Award from the NIH, the Milton Fund Award from Harvard
Medical School, and the Henry Christian Award from the American Federation for
Clinical Research. He serves on the editorial boards of Stem Cells and the American
Cancer Society’s Cancer Information Database and on numerous review committees
4
Agenda Item # 9 a
10/11/06 ICOC Meeting
including as chairman of the Peer Review Committee on Leukemia, Immunology, and
Blood Cell Development, the Council for Extramural Grants for the American Cancer
Society, the Scientific Subcommittee on Myeloid Biology of the American Society of
Hematology and review panels of the NIH. His primary research interest is the regulation
of transcription in myeloid differentiation.
Janet Rossant, PhD
Dr. Janet Rossant is Professor at the University of Toronto and Chief of Research and
Senior Scientist at the Hospital for Sick Children in Toronto. In addition, she is the
Deputy Director of the Canadian Stem Cell Networks Centers of Excellence and Director
of the Centre for Modelling Human Disease in Toronto which is undertaking genome-
wide mutagenesis in mice to develop new mouse models of human disease. Trained at
the Universities of Cambridge (PhD) and Oxford (post-doctoral fellow) in the United
Kingdom, Dr. Rossant is a Fellow of both the Royal Societies of London and Canada as
well as of the American Association for the Advancement of Science and a Distinguished
Investigator of the Canadian Institutes of Health Research (CIHR). A past editor of the
journal Development and president of the Society for Developmental Biology in 1996/97,
she has been involved in public issues related to developmental biology, most recently
serving as chair of the CIHR working group on stem cell research, and participated in the
development of the National Academies Guidelines for Embryonic Stem Cell Research
published in May 2005. She is a member of the Governing Council of the CIHR and the
Scientific Advisory Boards of the Stowers Institute, the Genomic Institute of Singapore
and the Australian Stem Cell Network as well as on the External Advisory Board of the
Max Planck Institute for Cell Biology. Dr. Rossant has served on numerous grant review
committees for the HHMI Scientific Review Board, the CIHR Genomic Grants
Committee, multiple MRC panels and the NIH. Her research interests center on
understanding the genetic control of normal and abnormal development in the early
mouse embryo; she is well known particularly her discovery of a novel placental stem
cell type, the trophoblast stem cell.
Michael Rudnicki, PhD
Michael Rudnicki received his PhD from the University of Ottawa in 1988 with Dr.
Michael McBurney, then trained with Dr. Rudolf Jaenisch at the Whitehead Institute at
the Massachusetts Institute of Technology. He is Professor of Medicine at the University
of Ottawa, Scientific Director of the Ontario Genomics Innovation Center, an
International Scholar of the Howard Hughes Medical Institute and holds the Canada
Research Chair in Molecular Genetics. In 2001, Dr. Rudnicki was appointed director of
the Molecular Medicine Program at the Ottawa Health Research Institute (OHRI); in
2005, he was appointed Scientific Director of the Canadian Stem Cell Network and he
will be the Director of the new Centre for Stem Cell and Gene Therapy when it opens at
the OHRI. He is also Scientific Director of the Stem Cell Genomics Project, a $10.6
million initiative to identify genes that regulate stem cell function. He was involved as a
founding scientist in the formation of an OHRI spin off biotech company StemPath. Dr.
Rudnicki's laboratory employs molecular genetic approaches to determine the function
and roles played by regulatory genes acting in pathways that regulate cellular
proliferation and differentiation of stem cells.
5
Agenda Item # 9 a
10/11/06 ICOC Meeting
Harinder Singh, PhD
Dr. Singh is the Louis Block Professor of Molecular Genetics and Cell Biology and
Howard Hughes Medical Institute Investigator at the University of Chicago. He obtained
his PhD from Northwestern University, working with Dr. Lawrence Dumas and was a
Jane Coffin Childs postdoctoral fellow in the laboratory of Dr. Phillip Sharp at the
Massachusetts Institute of Technology. At the University of Chicago, Dr. Singh serves as
Director of the Molecular and Cellular Biology Training Grants, as Chair of the Stem Cell
Biology Initiative and Director of the Interdisciplinary Scientist Training Program. He has
a great deal of experience in review having chaired and served on many review panels
for the NIH and the Leukemia and Lymphoma Society and as a member of the Board of
Scientific Counselors at the National Cancer Institute. He has published extensively on
the mammalian immune system and cellular differentiation. His current research focus is
on analyzing transcription factors that control gene activity and development of the
immune system.
Lorenz Studer, MD
A native of Switzerland, Dr. Lorenz Studer graduated from medical school in 1991 and
received his doctoral degree in neuroscience at the University of Bern in 1994. While
there, he initiated studies with Dr. Christian Spenger leading to the first clinical trial of
fetal tissue transplantation for Parkinson's disease in Switzerland in December 1995. He
then worked as a visiting Associate in Dr. Ron McKay’s laboratory at the NIH before
accepting a joint appointment as an Assistant Member in Developmental Biology and
Neurosurgery at the Sloan-Kettering Institute and as an Assistant Professor at Cornell
Medical School in New York. He is currently an Associate Member of the Sloan-
Kettering Institute and an Associate Professor of Developmental Neurobiology at Cornell
Medical School. At the NIH he pioneered tissue culture techniques that led to the
generation of dopamine cells from dividing precursor cells. In 1998, he demonstrated
that upon transplantation, such dopamine cells improve clinical symptoms in
Parkinsonian rats. Studer then went on to show that virtually unlimited numbers of
cultured mouse dopamine cells could be obtained from embryonic stem cells. Major
recent contributions of his laboratory include the in vitro derivation of midbrain dopamine
neurons from adult mouse somatic cells via nuclear transfer. As a result of his seminal
contributions to science, Dr. Studer has been honored by numerous awards. He also
serves on many review panels including several for the NIH, the Michael J. Fox
Research Foundation, the Juvenile Diabetes Research Foundation and the Biomedical
Research Council of Singapore.
Amy J. Wagers, PhD
Amy Wagers received her PhD in Immunology and Microbial Pathogenesis from
Northwestern University in 1999, and then worked as a postdoctoral fellow studying
stem cell biology in the laboratory of Dr. Irving Weissman in the Department of
Pathology at Stanford University School of Medicine. Since May 2004, she has been an
Assistant Professor in the Section on Developmental and Stem Cell Biology at Joslin
Diabetes Center and the Department of Pathology at Harvard Medical School. She is
also a Principal Faculty member of the Harvard Stem Cell Institute, serving on its
Executive Steering Committee and heading its Junior Faculty Program. She was
recently appointed to the State of Connecticut Stem Cell Research Advisory Committee
and is a recipient of the Burroughs Wellcome Fund Career Award in the Biomedical
6
Agenda Item # 9 a
10/11/06 ICOC Meeting
Sciences and the Smith Family New Investigator Award. Her current research focuses
on defining the factors and mechanisms that regulate the migration, expansion, and
regenerative potential of adult blood-forming and muscle-forming stem cells.
John E. Wagner, MD
Dr. John Wagner is Professor of Pediatrics in the Division of Hematology-Oncology and
Blood and Marrow Transplantation and holds the Albert and Eva Corniea Chair of
Clinical Research and Variety Club Chair in Molecular and Cellular Therapeutics at the
University of Minnesota. After receiving his MD degree at Jefferson Medical College in
1981, he completed his internship and residency at Duke University School of Medicine
in 1984 and a post-doctoral fellowship in Hematology-Oncology at the Johns Hopkins
School of Medicine. Internationally recognized as an expert in the field of hematopoietic
stem cell transplantation, he is board certified in Pediatrics and Hematology/Oncology
and serves as Scientific Director of the Clinical Research Blood and Marrow Transplant
Program and Director of the Clinical Trials Office at the University of Minnesota Cancer
Center. Dr. Wagner has served on numerous national and international scientific
advisory committees including for the NIH-NHLBI, National Marrow Donor Program,
Society of Hematotherapy and Graft Engineering, the FDA Biological Response
Modifiers Advisory Committee and the American Association of Blood Banks and has
made significant contributions as a scientist/clinician member of the CIRM’s Standards
Working Group. In addition, he has reviewed proposals for several prestigious granting
organizations including the Wellcome Trust, National Institute for Biological Sciences,
Israel Science Foundation, the National Research Institute (Taiwan) and the Swiss
Science Foundation. Dr. Wagner’s research is focused on the development of novel
strategies for preventing the immunologic complications of allogeneic hematopoietic
stem cell transplantation, namely through bone marrow graft engineering and the use of
neonatal umbilical cord blood.
David A. Williams, MD
David Williams is the Beatrice G. Lampkin Professor of Pediatrics,Associate Chairman
for Translational Research at the University of Cincinnati College of Medicine and
Director of the Division of Experimental Hematology of the Cincinnati Children’s
Research Foundation. After receiving his MD with distinction from Indiana University
School of Medicine, he completed his residency at Cincinnati’s Children’s Hospital
Medical Center and served as a research fellow and clinical fellow at Harvard Medical
School and the Dana-Farber Cancer Institute in Boston. The recipient of numerous
honors, his awards include the William Dameshek Award from the American Society of
Hematology (2000), the Samuel Rosenthal Prize for Excellence in Pediatrics (2002),
membership in the Institute of Medicine, National Academy of Sciences (2003), the
Frank Oski Award and the Donald Metcalf Award from the International Society of
Experimental Hematology (2006). Dr. Williams has filed numerous patents, has
published widely and has vast experience on review panels. Research in Dr. Williams'
laboratory focuses on understanding the biology of hematopoietic stem cells and
development of gene transfer methods for application in the treatment of severe genetic
diseases of the blood system.
7


Use: 0.3937